Clinical use of dornase alfa is associated with a slower rate of FEV 1 decline in cystic fibrosis

Pediatric Pulmonology

Volumn 46, Issue 6, 2011, Pages 545-553

  Konstan, Michael W ^a,f   Wagener, Jeffrey S ^b   Pasta, David J ^c   Millar, Stefanie J ^c   Jacobs, Joan R ^d   Yegin, Ashley ^d   Morgan, Wayne J ^e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c ICON CLINICAL RESEARCH   (United States)

^d GENENTECH INC   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cystic fibrosis; dornase alfa; epidemiology; pulmonary function

Indexed keywords

DORNASE ALFA; DEOXYRIBONUCLEASE I; DNASE1 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; LONGITUDINAL STUDY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 79955909454     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21388     Document Type: Article

References (18)

1. Konstan MW, Berger M,. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 24: 137-142. (Pubitemid 27450731)
2. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL,. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192. (Pubitemid 120030590)
3. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642. (Pubitemid 24276863)
4. McCoy K, Hamilton S, Johnson C,. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996; 110: 889-895. (Pubitemid 26347599)
5. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW,. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820. (Pubitemid 34014460)
6. Davis PB, Byard PJ, Konstan MW,. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997; 41: 161-165. (Pubitemid 27066337)
7. Johnson CA, Butler SM, Konstan MW, Breen TJ, Morgan WJ,. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. J Pediatr 1999; 134: 734-739. (Pubitemid 30186818)
8. Morgan WJ, Butler SM, Johnson CA, Colin AA, Fitzsimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S,. Epidemiologic Study of Cystic Fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28: 231-241. (Pubitemid 29468456)
9. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG, Jr., Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15: 75-88.
10. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187. (Pubitemid 29036522)
11. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ,. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008; 153: 746-751.
12. Corey M, Edwards L, Levison H, Knowles M,. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997; 131: 809-814. (Pubitemid 28027602)
13. Schluchter MD, Konstan MW, Davis PB,. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002; 21: 1271-1287. (Pubitemid 34467234)
14. Konstan MW, Byard PJ, Hoppel CL, Davis PB,. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
15. Konstan MW, Schluchter MD, Wei X, Davis PB,. Clinical use of ibuprofen is associated with slower rate of FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084-1089. (Pubitemid 350223754)
16. Rothman KJ, Wentworth CE, III., Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation. Epidemiology 2003; 14: 55-59. (Pubitemid 40416810)
17. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME,. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003; 123: 20-27. (Pubitemid 36126709)
18. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA,. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151: 134-139.